Naoko Takebe to Combined Modality Therapy
This is a "connection" page, showing publications Naoko Takebe has written about Combined Modality Therapy.
Connection Strength
0.337
-
Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836.
Score: 0.128
-
Perspectives on research activity in the USA on Cancer Precision Medicine. Jpn J Clin Oncol. 2016 Feb; 46(2):106-10.
Score: 0.119
-
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
Score: 0.029
-
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011 Feb 15; 17(4):654-66.
Score: 0.021
-
Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant. 2006 Jan; 37(1):65-72.
Score: 0.015
-
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant. 2004 Apr; 33(8):781-7.
Score: 0.013
-
Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant. 2002 Feb; 29(4):303-12.
Score: 0.011